tadalafil has been researched along with Cardiac Remodeling, Ventricular in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badagliacca, R; Barbagallo, F; Barbano, B; Caboni, P; Campolo, F; Carbone, I; Catalano, C; Ciolina, F; Defeudis, G; Feola, T; Filardi, T; Francone, M; Galea, N; Gianfrilli, D; Giannetta, E; Isidori, AM; Lenzi, A; Minnetti, M; Pasqualetti, P; Pofi, R; Pozzilli, P; Sesti, F; Venneri, MA; Vizza, CD | 1 |
| Argiento, P; Badagliacca, R; D'Alto, M; Farro, A; Golino, P; Naeije, R; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Vizza, CD | 1 |
| Becker, LK; Caldwell, JL; Church, SJ; Dibb, KM; Eisner, DA; Hutchings, DC; Kirkwood, GJ; Lawless, M; Madders, GWP; Pearman, CM; Radcliffe, EJ; Smith, CER; Taylor, RF; Trafford, AW; Unwin, RD; Woods, LS | 1 |
| Bach, L; Geenen, D; Raghavan, A; Raj, JU; Ramchandran, R; Sun, M; Yang, Q | 1 |
| Chau, VQ; Hoke, NN; Kukreja, RC; Salloum, FN | 1 |
| Abbate, A; Chau, VQ; Hoke, NN; Kukreja, RC; Ockaili, RA; Salloum, FN; Toldo, S; Varma, A | 1 |
| Kass, DA | 1 |
| Kukreja, RC | 1 |
1 review(s) available for tadalafil and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.
Topics: Carbolines; Cardiomyopathy, Dilated; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Fibrosis; Heart; Heart Failure; Humans; Hypertrophy; Myocardium; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Transforming Growth Factor beta; TRPC Cation Channels; Ventricular Remodeling | 2012 |
1 trial(s) available for tadalafil and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial.
Topics: Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Mellitus, Type 2; Double-Blind Method; Erectile Dysfunction; Female; Humans; Kinetics; Male; MicroRNAs; Penile Erection; Phosphodiesterase 5 Inhibitors; Tadalafil; Treatment Outcome; Ventricular Remodeling | 2022 |
6 other study(ies) available for tadalafil and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
Topics: Adult; Antihypertensive Agents; Atrial Remodeling; Cardiac Catheterization; Drug Therapy, Combination; Echocardiography; Epoprostenol; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Risk Reduction Behavior; Tadalafil; Treatment Outcome; Vascular Resistance; Vasodilator Agents; Ventricular Function, Right; Ventricular Remodeling; Walk Test | 2020 |
Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure.
Topics: Animals; Catecholamines; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Heart Failure; Induced Pluripotent Stem Cells; Myocardial Contraction; Myocytes, Cardiac; Phosphodiesterase 5 Inhibitors; Sheep; Tadalafil; Ventricular Remodeling | 2019 |
PKG-1α leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension.
Topics: Animals; Carbolines; Cell Hypoxia; Cells, Cultured; Cyclic GMP-Dependent Protein Kinase Type I; Drug Evaluation, Preclinical; Female; Gene Expression; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Mutation; Myocytes, Smooth Muscle; Pulmonary Artery; Pulmonary Circulation; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Tadalafil; Vasodilation; Vasodilator Agents; Ventricular Remodeling | 2014 |
Tadalafil prevents acute heart failure with reduced ejection fraction in mice.
Topics: Animals; Apoptosis; Carbolines; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Heart Failure; Male; Mice; Mice, Inbred ICR; Myocardial Infarction; Phosphodiesterase Inhibitors; Pulmonary Edema; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide.
Topics: Animals; Carbolines; Cyclic GMP-Dependent Protein Kinases; Cystathionine beta-Synthase; Female; Hemodynamics; Hydrogen Sulfide; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil; Ventricular Remodeling | 2009 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |